Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER networkLoreta A. Kondili, Stefano Vella, Giovanni Battista Gaeta et al.|PLoS ONE|2017Cited by 114
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A. Kondili, Massimo Puoti, Giovanni Battista Gaeta et al.|PLoS ONE|2017Cited by 46
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factorsRaffaella Bucciardini, Marco Floridia, Giovanni Guaraldi et al.|International Journal of STD & AIDS|2012Cited by 10
Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based RegimensSilvia Baroncelli, Marco Floridia, Maria Franca Pirillo et al.|AIDS Research and Human Retroviruses|2014Cited by 10
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A. Kondili, Massimo Puoti, Giovanni Battista Gaeta et al.|PLoS ONE|2018Cited by 5